FAQs
The following is a list of frequently asked questions about TIMOPTIC® in OCUDOSE® that may not have been specifically addressed on our site:
How long does it take for TIMOPTIC® in OCUDOSE® to reduce IOP?
Will my patient always have to take TIMOPTIC® in OCUDOSE® twice a day?
After the OCUDOSE® unit is opened, how long can the patient wait to administer the eye drop(s)?
Is TIMOPTIC® in OCUDOSE® covered by most managed care plans?
Where can my patient fill his or her prescription for TIMOPTIC® in OCUDOSE®?
Where should I report adverse events experienced by my patients while
using TIMOPTIC® in OCUDOSE®?
What if I still have a question that wasn’t covered here?
I am a pharmacist. How can I place an order for TIMOPTIC® in OCUDOSE®?
How long does it take for TIMOPTIC® in OCUDOSE® to reduce IOP?
Following administration of a single dose of TIMOPTIC®, the reduction of IOP can be detected within one-half hour.1
Will my patient always have to take TIMOPTIC® in OCUDOSE® twice a day?
Yes, when first starting on treatment, TIMOPTIC® in OCUDOSE® should be taken twice a day, because some patients require more time for their IOP to stabilize. After four weeks, IOP should be evaluated.1
If IOP is maintained at satisfactory levels, dosage administration can be changed to one drop per day in the affected eye(s).
After the OCUDOSE® unit is opened, how long can the patient wait to administer the eye drop(s)?
Administration of the solution should occur immediately after opening. Since the solution is sterile and does not contain a preservative, sterility cannot be guaranteed after the unit it opened, and remaining contents should be discarded.1
Is TIMOPTIC® in OCUDOSE® covered by most managed care plans?
Yes, TIMOPTIC® in OCUDOSE® is covered by most plans. A knowledgeable representative can address any question you may have about TIMOPTIC® in OCUDOSE® or managed care. Your patient can reach Valeant Patient Assistance directly by calling (866) 268-7325, Monday – Friday 9am-5pm (except holidays) for more information on Valeant Patient Assistance.
You can save up to $100 off your prescription copay through this offer.
Where can my patient fill his or her prescription for TIMOPTIC® in OCUDOSE®?
Valeant is committed to ensuring that supplies of TIMOPTIC® in OCUDOSE® are available for your patient when needed. When you write a TIMOPTIC® in OCUDOSE® prescription, your patient has the convenience of going to any local pharmacy in the United States.
Where should I report adverse events experienced by my patients while using TIMOPTIC® in OCUDOSE®?
If your patient has experienced an adverse event using TIMOPTIC® in OCUDOSE®, contact one of our medical specialists at Valeant Pharmaceuticals Medical Affairs at (877) 361-2719.
What if my patient has a question that was not covered here?
If your patient has a question that was not covered here, you can advise your patients to contact Customer Service at Valeant Pharmaceuticals at (800) 321-4576 or by email at pharmcs@valeant.com or to contact the Valeant Patient Assistance Program at (866) 268-7325.
I am a pharmacist. How can I place an order for TIMOPTIC® in OCUDOSE®?
TIMOPTIC® in OCUDOSE® is available in the United States.
INDICATIONS AND USAGE
Preservative-free TIMOPTIC® in OCUDOSE® is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Preservative-free TIMOPTIC® in OCUDOSE® may be used when a patient is sensitive to the preservative in Timoptic (timolol maleate ophthalmic solution), benzalkonium chloride, or when use of a preservative-free topical medication is advisable.
IMPORTANT SAFETY INFORMATION
Timoptic is contraindicated in patients with: bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease; sinus bradycardia; second or third degree atrioventricular block; overt cardiac failure; cardiogenic shock; hypersensitivity to any component of this product.
This drug is absorbed systemically. The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. Severe respiratory or cardiac reactions, including death, have been reported following systemic or ophthalmic administration of timolol maleate. Timoptic should be used with caution in patients with cerebrovascular insufficiency.
The most frequently reported adverse experiences have been burning and stinging upon instillation.
Please see full Prescribing Information by clicking on the link above.
References: 1. Timoptic (timolol maleate ophthalmic solution) in Ocudose (dispenser) [prescribing information]. Lawrenceville, NJ: Aton Pharma, Inc; 2009.
